<DOC>
	<DOCNO>NCT02906254</DOCNO>
	<brief_summary>Febrile neutropenia require prompt initiation broad-spectrum antibiotic , responsible side-effects selection resistance . This study demonstrate safety early discontinuation empirical treatment , carefully select patient present fever unknown origin .</brief_summary>
	<brief_title>Early Antibiotic Discontinuation FUO</brief_title>
	<detailed_description>Infections responsible significant morbidity mortality haematological patient , particular chemotherapy-induced neutropenia . Guidelines recommend immediate initiation antibiotic therapy , whose optimal duration unclear . The primary objective study evaluate early discontinuation antibiotic treatment Fever Unknown Origin ( FUO ) afebrile febrile neutropenic patient . The secondary objective describe epidemiology febrile neutropenia ( FN ) investigator centre . Every episode FN prospectively identify . In first phase study , empirical antibiotic therapy FUO patient stop 48 hour apyrexia , accordance ECIL-4 ( European Conference Infections Leukaemia ) recommendation . In second phase study , antibiotic stop day 5 FUO patient , regardless temperature leukocyte count .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>age ≥ 18 year ; presence malignant haematological disease combine chemotherapyinduced neutropenia ( polymorphonuclear neutrophil ( PMN ) count ≤ 500/mm3 ) fever define tympanic temperature ≥38°C ≥1 hour single temperature ≥38.3°C Patients without curative care chronic neutropenia ( PMN≤ 500/mm3 3 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>